Literature DB >> 3805530

Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise.

J S Steinberg, R J Katz, G B Bren, L A Buff, P J Varghese.   

Abstract

Although digoxin is often the first choice for control of ventricular response in chronic atrial fibrillation, it fails to slow exercise rates. Diltiazem, a calcium channel antagonist that slows atrioventricular conduction, was administered to 16 patients who failed to achieve adequate rate control on low level exercise testing despite digoxin therapy. Therapeutic response to diltiazem was assessed with submaximal and maximal exercise tests and 24 hour ambulatory electrocardiographic monitoring. During the diltiazem treatment phase, ventricular response at rest diminished (96 +/- 17 versus 69 +/- 10 beats/min, p less than 0.001) as did rate during submaximal exercise (155 +/- 28 versus 116 +/- 26, p less than 0.001), maximal exercise (163 +/- 14 versus 133 +/- 26, p less than 0.001) and average ventricular response during 24 hour monitoring (87 +/- 13 versus 69 +/- 10, p less than 0.001). Rate at rest decreased 26 +/- 15% and submaximal exercise rate diminished 24 +/- 12%. Thirteen (81%) of the 16 patients exhibited at least 15% slowing of rate at rest and during submaximal exercise. Eleven patients (69%) reported alleviation of symptoms. There was no change in serum digoxin levels during diltiazem treatment (1.3 +/- 0.5 versus 1.3 +/- 0.6 ng/ml, p = NS). On withdrawal of diltiazem, ventricular response returned to baseline values. Diltiazem is an effective agent for control of ventricular response, both at rest and during exercise, in digoxin-treated patients with chronic atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3805530     DOI: 10.1016/s0735-1097(87)80396-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  14 in total

Review 1.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

2.  Rate control in atrial fibrillation: what approach is best?

Authors:  Brian Olshansky
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

3.  Influence of physical exercise on serum digoxin concentration and heart rate in patients with atrial fibrillation.

Authors:  H E Bøtker; P Toft; N A Klitgaard; E E Simonsen
Journal:  Br Heart J       Date:  1991-06

4.  Rate control in permanent atrial fibrillation.

Authors:  Theodora Nikolaidou; Kevin S Channer
Journal:  BMJ       Date:  2007-11-24

Review 5.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

7.  The drug treatment of atrial fibrillation.

Authors:  K S Channer
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 8.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

9.  Mechanical and electrophysiological effects of 8-oxoberberine (JKL1073A) on atrial tissue.

Authors:  J F Chi; S H Chu; C S Lee; N K Chou; M J Su
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

10.  Automatically finding relevant citations for clinical guideline development.

Authors:  Duy Duc An Bui; Siddhartha Jonnalagadda; Guilherme Del Fiol
Journal:  J Biomed Inform       Date:  2015-09-10       Impact factor: 6.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.